Bill Sponsor
House Bill 7717
118th Congress(2023-2024)
To amend title XI of the Social Security Act to enhance pharmacy benefit manager transparency requirements.
Introduced
Introduced
Introduced in House on Mar 19, 2024
Overview
Text
Introduced in House 
Mar 19, 2024
No Linkage Found
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Mar 19, 2024)
Mar 19, 2024
No Linkage Found
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
H. R. 7717 (Introduced-in-House)


118th CONGRESS
2d Session
H. R. 7717


To amend title XI of the Social Security Act to enhance pharmacy benefit manager transparency requirements.


IN THE HOUSE OF REPRESENTATIVES

March 19, 2024

Mr. Gallego introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


A BILL

To amend title XI of the Social Security Act to enhance pharmacy benefit manager transparency requirements.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Enhancing PBM transparency requirements.

(a) In general.—Section 1150A of the Social Security Act (42 U.S.C. 1320b–23) is amended—

(1) by striking subsection (a) and inserting the following:

“(a) Provision of information.—

“(1) IN GENERAL.—The following entities shall provide the information described in subsection (b) to the Secretary and, in the case of an entity described in subparagraph (B) or an affiliate of such entity described in subparagraph (C), to the health benefits plan with which the entity is under contract, at such times, and in such form and manner, as the Secretary shall specify:

“(A) A health benefits plan.

“(B) Any entity that provides pharmacy benefits management services on behalf of a health benefits plan (in this section referred to as a ‘PBM’) that manages prescription drug coverage under a contract with—

“(i) a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan under part D of title XVIII; or

“(ii) a qualified health benefits plan offered through an exchange established by a State under section 1311 of the Patient Protection and Affordable Care Act.

“(C) Any affiliate of an entity described in subparagraph (B) that acts as a price negotiator or group purchaser on behalf of such PBM, PDP sponsor, MA organization, or qualified health benefits plan.

“(2) AFFILIATE DEFINED.—In this section, the term ‘affiliate’ means any entity that is owned by, controlled by, or related under a common ownership structure with a PBM (including an entity owned or controlled by the PDP sponsor of a prescription drug plan, MA organization offering an MA–PD plan, or qualified health benefits plan for which such entity is acting as a price negotiator or group purchaser).”;

(2) in subsection (b)—

(A) in paragraph (2), by inserting “and percentage” after “and the aggregate amount”; and

(B) by adding at the end the following new paragraph:

“(4) The amount (in the aggregate and disaggregated by type) of all fees the PBM or an affiliate of the PBM receives from all pharmaceutical manufacturers in connection with patient utilization under the plan, and the amount and percentage (in the aggregate and disaggregated by type) of such fees that are passed through to the plan sponsor or issuer.”; and

(3) by adding at the end the following new subsection:

“(e) Annual report.—The Secretary shall make publicly available on the Internet website of the Centers for Medicare & Medicaid Services an annual report that summarizes the trends observed with respect to data reported under subsection (b).”.

(b) Effective date.—The amendments made by this section shall apply to plan or contract years beginning on or after January 1, 2027.

(c) Implementation.—Notwithstanding any other provision of law, the Secretary may implement the amendments made by this section by program instruction or otherwise.

(d) Non-Application of the paperwork reduction act.—Chapter 35 of title 44, United States Code (commonly referred to as the “Paperwork Reduction Act of 1995”), shall not apply to the implementation of the amendments made by this section.